Jennifer G Whisenant
Overview
Explore the profile of Jennifer G Whisenant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajagopal P, Reid S, Fan R, Venton L, Weidner A, Roberson M, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):28.
PMID: 40069179
We determined triple-negative breast cancer (TNBC) subtypes, genetic ancestry, and immune features in a cohort of self-reported Black females with TNBC diagnosed at or below age 50. Among 104 tumors,...
2.
Ciombor K, Bae S, Whisenant J, Ayers G, Sheng Q, Peterson T, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39927885
Purpose: EGFR-targeting monoclonal antibodies are essential for managing RAS WT metastatic colorectal cancer (mCRC), but their limited efficacy necessitates exploring immunological and metabolic factors influencing response. This study evaluated glutamine...
3.
Myall N, Whisenant J, Neal J, Iams W, Reckamp K, York S, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100757.
PMID: 39866193
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may...
4.
Reid S, Fan R, Venton L, Weidner A, Tezak A, Roberson M, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449798.
PMID: 39652347
Importance: Young Black women bear a disproportionate burden of breast cancer deaths compared with White women, yet they remain underrepresented in genomic studies. Objective: To evaluate the association of biological...
5.
Beckermann K, Bestvina C, El Osta B, Sanborn R, Borghaei H, Lammers P, et al.
JTO Clin Res Rep
. 2024 Feb;
5(2):100619.
PMID: 38328473
Introduction: Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested the safety and efficacy of vorolanib, a novel tyrosine...
6.
Burns L, Hsu C, Whisenant J, Marmarelis M, Presley C, Reckamp K, et al.
Lung Cancer
. 2023 Nov;
186:107423.
PMID: 37995456
Background: Patients with thoracic malignancies who develop COVID-19 infection have a higher hospitalization rate compared to the general population and to those with other cancer types, but how this outcome...
7.
Lander E, Li X, Huang L, Cass A, Iams W, Skotte E, et al.
J Natl Compr Canc Netw
. 2023 Oct;
21(10):1050-1057.e13.
PMID: 37856197
Background: More than 50% of patients with lung cancer are admitted to the hospital while receiving treatment, which is a burden to patients and the healthcare system. This study characterizes...
8.
Reid S, Roberson M, Koehler K, Shah T, Weidner A, Whisenant J, et al.
JAMA Oncol
. 2022 Nov;
9(1):143-145.
PMID: 36326735
No abstract available.
9.
Bestvina C, Whisenant J, Torri V, Cortellini A, Wakelee H, Peters S, et al.
JTO Clin Res Rep
. 2022 May;
3(8):100335.
PMID: 35619644
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa...
10.
Cardin D, Gilbert J, Whisenant J, Ayers G, Jalikis F, Dahlman K, et al.
Clin Colorectal Cancer
. 2022 Apr;
21(3):236-243.
PMID: 35450836
Introduction: Small bowel adenocarcinomas (SBAs) are rare and frequently treated like large intestinal adenocarcinomas. However, SBAs have a very different microenvironment and could respond differently to the same therapies. Our...